We retrospectively collected 205 three-dimensional T1-weighted (3D-T1) sequence non-gadolinium contrast-enhanced MR images with an axial slice thickness of 1 mm from the First People’s Hospital of Hangzhou between January 2019 and June 2019. The data set was then randomly assigned to two cohorts: 140 cases were used to construct the AD tool and 35 cases were used to optimize its hyperparameters, and the remaining 30 cases were assigned to a testing cohort a. Considering that 3D-T1 MRI is not routinely used in clinical practice, we also collected external cases with non-3D-T1 MRI to test the performance of this AD tool. This includes 19 non-3D T1-weighted non-gadolinium contrast-enhanced MRIs with an axial slice thickness of 3 mm from Shanghai Chest Hospital between July 2019 and September 2019 (testing cohort b) and 11 non-3D T1-weighted gadolinium contrast-enhanced MRIs with an axial slice thickness of 1 mm from Hangzhou Cancer Hospital between July 2019 and September 2019 (testing cohort c). All the cases were > 18 years old, and the MRIs confirmed with normal hippocampus has not been violated by any disease. The MRI Machine Vendor in train cohort and testing cohort a is GE 3.0 T Signa. In testing cohort b and c is Siemens 1.5T Aera.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.